Essex Bio-Technology Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Essex Bio-Technology.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 41.1% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement
Oct 09Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's
Aug 29Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement
May 06Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Mar 21Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04
Aug 25Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055
May 02Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055
Mar 30Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today
Mar 13How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?
Feb 15Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?
Jan 25Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 04Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters
Nov 23In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Essex Bio-Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2024 | 1,619 | 263 | 211 | 316 | N/A |
3/31/2024 | 1,663 | 269 | 211 | 328 | N/A |
12/31/2023 | 1,707 | 275 | 211 | 339 | N/A |
9/30/2023 | 1,634 | 266 | 169 | 323 | N/A |
6/30/2023 | 1,561 | 256 | 127 | 307 | N/A |
3/31/2023 | 1,439 | 241 | 113 | 345 | N/A |
12/31/2022 | 1,318 | 225 | 100 | 383 | N/A |
9/30/2022 | 1,437 | 274 | 103 | 406 | N/A |
6/30/2022 | 1,556 | 323 | 106 | 430 | N/A |
3/31/2022 | 1,597 | 334 | 130 | 419 | N/A |
12/31/2021 | 1,638 | 346 | 154 | 409 | N/A |
9/30/2021 | 1,515 | 339 | 124 | 430 | N/A |
6/30/2021 | 1,392 | 332 | 94 | 451 | N/A |
3/31/2021 | 1,185 | 275 | 32 | 375 | N/A |
12/31/2020 | 978 | 219 | -31 | 299 | N/A |
9/30/2020 | 1,000 | 221 | 13 | 253 | N/A |
6/30/2020 | 1,022 | 222 | 57 | 207 | N/A |
3/31/2020 | 1,151 | 262 | 57 | 220 | N/A |
12/31/2019 | 1,279 | 303 | 57 | 233 | N/A |
9/30/2019 | 1,238 | 282 | 32 | 213 | N/A |
6/30/2019 | 1,197 | 262 | 8 | 194 | N/A |
3/31/2019 | 1,187 | 246 | 53 | 197 | N/A |
12/31/2018 | 1,176 | 231 | 99 | 201 | N/A |
9/30/2018 | 1,100 | 210 | 119 | 207 | N/A |
6/30/2018 | 1,023 | 189 | 138 | 214 | N/A |
3/31/2018 | 961 | 178 | N/A | 204 | N/A |
12/31/2017 | 900 | 167 | N/A | 194 | N/A |
9/30/2017 | 874 | 159 | N/A | 166 | N/A |
6/30/2017 | 849 | 151 | N/A | 138 | N/A |
3/31/2017 | 813 | 144 | N/A | 114 | N/A |
12/31/2016 | 776 | 136 | N/A | 90 | N/A |
9/30/2016 | 740 | 126 | N/A | 63 | N/A |
6/30/2016 | 705 | 115 | N/A | 37 | N/A |
3/31/2016 | 679 | 110 | N/A | 53 | N/A |
12/31/2015 | 654 | 105 | N/A | 69 | N/A |
9/30/2015 | 627 | 101 | N/A | 75 | N/A |
6/30/2015 | 600 | 96 | N/A | 81 | N/A |
3/31/2015 | 559 | 86 | N/A | 58 | N/A |
12/31/2014 | 518 | 75 | N/A | 35 | N/A |
9/30/2014 | 466 | 67 | N/A | 43 | N/A |
6/30/2014 | 413 | 59 | N/A | 51 | N/A |
3/31/2014 | 380 | 57 | N/A | 58 | N/A |
12/31/2013 | 347 | 55 | N/A | 65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1061's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 1061's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1061's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1061's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 1061's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1061's Return on Equity is forecast to be high in 3 years time